Pfizer shares fell more than 3% Tuesday after newly acquired Metsera released underwhelming mid-stage trial results.
Driving the news: A Phase 2 trial result released Tuesday showed Metsera's MET-097i (rebranded to PF-3944 post acquisition) drove weight loss of up to 10.5% after roughly six months, just shy of the efficacy of Eli Lilly's Zepbound.
